Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track FDMT with free AI briefings, catalyst countdowns, and dilution alerts.

FDMT · 4D Molecular Therapeutics, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$375M Cash on Hand
17.8mo Cash Runway
Follow FDMT by email Get an email when FDMT reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about FDMT, unsubscribe in one click. Privacy

📣 What FDMT Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
4D-150 IVT Neovascular Age-Related Macular Degeneration (nAMD) Phase 3 · NCT07064759 Recruiting
EYELEA ® (aflibercept) Injection 2 mg (0.05mL) Diabetic Macular Edema (DME) Phase 3 · NCT07867080 Recruiting
4D-125 IVT Injection X-Linked Retinitis Pigmentosa Phase 1/2 · NCT04517149 Active not recruiting
4D-310 Fabry Disease Phase 1/2 · NCT04519749 Active not recruiting
4D-710 Cystic Fibrosis Lung Phase 2 · NCT05248230 Recruiting
4D-110 Choroideremia Phase 1 · NCT04483440 Active not recruiting

Also used in these trials (approved or third-party drugs, not FDMT's own candidates): Aflibercept.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

FDMT holds $375M in cash and short-term investments (as of Sep 30, 2026) and burns about $63.4M/quarter from operations, an estimated runway of 17.8 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 57 · Elevated

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when FDMT files for a raise →

👥 Who Owns FDMT

Insiders 1.6% Other 5%+ holders 6% Institutions (225 holders) 92.4% Public and other holders 0%
HolderTypeShares% of sharesAs of
BVF PARTNERS L P/IL Institution (13G, 5%+) 5,811,860 11.68% 2026-09-30
JANUS HENDERSON GROUP PLC Institution (13G, 5%+) 5,247,151 10.54% 2026-03-31
RA Capital Management, L.P. Institution (13G, 5%+) 5,105,622 10.26% 2026-03-31
THE GOLDMAN SACHS GROUP, INC. Institution (13G, 5%+) 4,286,077 8.61% 2025-12-31
Novo Holdings A/S 5%+ holder (13G) 3,000,000 6.03% 2026-09-30
David Kirn
President and Chief Executive Officer, D · +967,500 options
Insider 709,153 1.42% 2026-10-05
Ashoo Gupta
VP, Finance and Controller · +3,087 options
Insider 47,055 0.09% 2026-03-20
Charles Theuer
Director · +50,000 options
Insider 41,684 0.08% 2025-12-12
Scott Bizily
Chief Legal Officer · +276,390 options
Insider 8,617 0.02% 2026-10-16

Share count 49,778,127 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full FDMT picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for FDMT and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.